The respiratory effects of oral ethyl loflazepate in volunteers.
A volunteer study was undertaken to assess the respiratory effects of ethyl loflazepate, a new benzodiazepine, and to correlate these with plasma concentrations of the active metabolites. Twelve volunteers were given placebo, 2 mg ethyl loflazepate, and 6 mg ethyl loflazepate on separate occasions. Respiration and plasma metabolite levels were assessed hourly for 8 h and at 24 h. The 6 mg ethyl loflazepate treatment produced a significant decrease (P less than 0.02) in the ventilatory response to carbon dioxide at 5 h. However this did not equate with a peak in plasma metabolite concentrations which were maintained at a plateau level from 4 to 24 h.
D000328:Adult; D014151:Anti-Anxiety Agents / Q000097:blood / Q000494:pharmacology*; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000097:blood / Q000494:pharmacology*; D001831:Body Temperature / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D005479:Flurazepam / Q000031:analogs & derivatives / Q000097:blood; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D012119:Respiration / Q000187:drug effects*; D012129:Respiratory Function Tests
D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; D001569:Benzodiazepines; D005479:Flurazepam; C029617:ethyl loflazepate; C020965:norflutoprazepam; C040581:loflazepic acid